Influence of Budesonide and Fluticasone Propionate in the Anti-osteoporotic Potential in Human Bone Marrow-derived Mesenchymal Stem Cells Via Stimulation of Osteogenic Differentiation

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Nov 5

PMID 39497989

Authors

Terrence Suministrado Sumague

Abdurahman A Niazy

Rhodanne Nicole A Lambarte

Ibrahim A Nafisah

Arief Gusnanto

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is a prevalent bone condition with adverse effects observed in patients undergoing long-term glucocorticoid therapy, resulting in bone demineralization and tissue loss. There has been limited studies on the global response to dexamethasone in terms of comparing its expression profile to other common glucocorticoids during osteogenic differentiation. This study focused on the downregulated gene expression profile of glucocorticoid compounds; dexamethasone, budesonide, and fluticasone propionate, during osteogenic differentiation to elucidate the related target genes and pathways associated with the anti-osteoporotic potential of telomerase-immortalized human bone marrow-derived mesenchymal stem cells using a bioinformatics approach. Based on gene expression microarrays experiments and bioinformatics analysis, several key genes involved in the regulation of osteogenic differentiation and osteoporosis development in mesenchymal stem cells that were targeted by these specific glucocorticoids were determined. Network analysis using GeneCards, OMIM, and CTD databases were performed and osteoporosis-related genes were identified. LIMMA and moderated Welch test R packages were performed to determine significant downregulated differentially expressed genes for each glucocorticoid treatment. A total of 479 (dexamethasone), 84 (budesonide), and 889 (fluticasone propionate) differentially expressed genes were identified for each glucocorticoid, of which 35 common genes overlapped. Enrichment pathway analysis was conducted using Metascape, and protein-protein interaction networks were constructed using the STRING database and Cytoscape software to determine potential target genes involved with osteoporosis. Enrichment pathway analysis revealed genes involved in 3 Reactome pathways namely cytokine signaling in immune system, immune system and the interferon alpha/beta signaling pathways and identified 10 hub genes based on the PPI network to determine potential target pathways associated with osteoporosis. These findings provide preliminary insights into the relationship between the key target genes of dexamethasone, budesonide, and fluticasone propionate, and the pathways associated with regulated osteoporosis metabolism during osteogenic differentiation.

References

Kato T, Khanh V, Sato K, Kimura K, Yamashita T, Sugaya H . Elevated Expression of Dkk-1 by Glucocorticoid Treatment Impairs Bone Regenerative Capacity of Adipose Tissue-Derived Mesenchymal Stem Cells. Stem Cells Dev. 2017; 27(2):85-99. DOI: 10.1089/scd.2017.0199. View

Park K, Park J, Lee S, Yoo K, Kweon G, Kwon I . Chi3L1 is a therapeutic target in bone metabolism and a potential clinical marker in patients with osteoporosis. Pharmacol Res. 2022; 184:106423. DOI: 10.1016/j.phrs.2022.106423. View

Abdallah B, Haack-Sorensen M, Burns J, Elsnab B, Jakob F, Hokland P . Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite [corrected] extensive proliferation. Biochem Biophys Res Commun. 2004; 326(3):527-38. DOI: 10.1016/j.bbrc.2004.11.059. View

Igarashi M, Kamiya N, Hasegawa M, Kasuya T, Takahashi T, Takagi M . Inductive effects of dexamethasone on the gene expression of Cbfa1, Osterix and bone matrix proteins during differentiation of cultured primary rat osteoblasts. J Mol Histol. 2004; 35(1):3-10. DOI: 10.1023/b:hijo.0000020883.33256.fe. View

Abrams S, OBrien K . Calcium and bone mineral metabolism in children with chronic illnesses. Annu Rev Nutr. 2004; 24:13-32. DOI: 10.1146/annurev.nutr.24.012003.132135. View

Song I, Caplan A, Dennis J . In vitro dexamethasone pretreatment enhances bone formation of human mesenchymal stem cells in vivo. J Orthop Res. 2009; 27(7):916-21. DOI: 10.1002/jor.20838. View

Xiong Q, Zhang L, Ge W, Tang P . The roles of interferons in osteoclasts and osteoclastogenesis. Joint Bone Spine. 2016; 83(3):276-81. DOI: 10.1016/j.jbspin.2015.07.010. View

Lupsa B, Insogna K . Bone Health and Osteoporosis. Endocrinol Metab Clin North Am. 2015; 44(3):517-30. DOI: 10.1016/j.ecl.2015.05.002. View

Zhytnik L, Maasalu K, Reimann E, Martson A, Koks S . RNA sequencing analysis reveals increased expression of interferon signaling genes and dysregulation of bone metabolism affecting pathways in the whole blood of patients with osteogenesis imperfecta. BMC Med Genomics. 2020; 13(1):177. PMC: 7684725. DOI: 10.1186/s12920-020-00825-7. View

10.

Hughes J, Conry B, Male S, Eastell R . One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density. Thorax. 1999; 54(3):223-9. PMC: 1745450. DOI: 10.1136/thx.54.3.223. View

11.

van Staa T, Leufkens H, Cooper C . The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13(10):777-87. DOI: 10.1007/s001980200108. View

12.

Wang C, Zhang X, Chen R, Zhu X, Lian N . EGR1 mediates METTL3/mA/CHI3L1 to promote osteoclastogenesis in osteoporosis. Genomics. 2023; 115(5):110696. DOI: 10.1016/j.ygeno.2023.110696. View

13.

Yu R, Zhang X, Xu W, Li Z, Zhu X . Apolipoprotein D alleviates glucocorticoid-induced osteogenesis suppression in bone marrow mesenchymal stem cells via the PI3K/Akt pathway. J Orthop Surg Res. 2020; 15(1):307. PMC: 7414572. DOI: 10.1186/s13018-020-01824-1. View

14.

Spiro A, Beil F, Schinke T, Schilling A, Eulenburg C, Rueger J . Short-term application of dexamethasone enhances bone morphogenetic protein-7-induced ectopic bone formation in vivo. J Trauma. 2010; 69(6):1473-80. DOI: 10.1097/TA.0b013e3181dc59e4. View

15.

Azevedo A, Prado A, Feldman S, de Figueiredo F, Dos Santos M, Issa J . MMPs are Involved in Osteoporosis and are Correlated with Cardiovascular Diseases. Curr Pharm Des. 2018; 24(16):1801-1810. DOI: 10.2174/1381612824666180604112925. View

16.

Schoon E, Bollani S, Mills P, Israeli E, Felsenberg D, Ljunghall S . Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol. 2005; 3(2):113-21. DOI: 10.1016/s1542-3565(04)00662-7. View

17.

Sorva R, Tahtela R, Turpeinen M, Juntunen-Backman K, Haahtela T, Risteli L . Changes in bone markers in children with asthma during inhaled budesonide and nedocromil treatments. Acta Paediatr. 1996; 85(10):1176-80. DOI: 10.1111/j.1651-2227.1996.tb18224.x. View

18.

Yuasa M, Yamada T, Taniyama T, Masaoka T, Xuetao W, Yoshii T . Dexamethasone enhances osteogenic differentiation of bone marrow- and muscle-derived stromal cells and augments ectopic bone formation induced by bone morphogenetic protein-2. PLoS One. 2015; 10(2):e0116462. PMC: 4319911. DOI: 10.1371/journal.pone.0116462. View

19.

Hopp R, Degan J, Phelan J, Lappe J, Gallagher G . Cross-sectional study of bone density in asthmatic children. Pediatr Pulmonol. 1995; 20(3):189-92. DOI: 10.1002/ppul.1950200311. View

20.

Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View